Download PDF
Semin Liver Dis 2018; 38(02): 121-133
DOI: 10.1055/s-0038-1657751
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Bacterial Infections in Acute-on-Chronic Liver Failure

Lingling Yang
1   State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
,
Tianzhou Wu
1   State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2   The Infectious Disease Department, The First People's Hospital of Wenling, Wenling, China
,
Jiang Li
1   State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
,
Jun Li
1   State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
› Author Affiliations
Further Information

Publication History

Publication Date:
05 June 2018 (online)

    Permissions and Reprints

Abstract

Acute-on-chronic liver failure (ACLF) is a newly recognized clinical syndrome characterized by preexisting chronic liver disease or cirrhosis with organ failure and high 28-day mortality (50–90%). Bacterial infections (BIs) play pivotal roles in the development and progression of ACLF either as a main precipitating event or a specific complication. The main organisms isolated as triggering ACLF are Gram-positive bacteria, followed by Gram-negative bacteria. Spontaneous bacterial peritonitis, pneumonia, urinary tract infections, and skin infections are prevalent infections that trigger and complicate ACLF. Despite appropriate antibiotic treatment, BIs account for poor ACLF outcomes and lead to a worse clinical course and higher intensive care unit admission and short-term mortality. Early diagnosis and novel nonantibiotic methods are highly important for managing BIs. Thus, this review focuses on the epidemiology, prognosis, and diagnosis of and management strategies for BIs in ACLF patients as well as the relationship between BIs and ACLF.

Keywords

bacterial infections - acute-on-chronic liver failure - prognosis - prophylaxis

Financial Support

None.


 

  • References

  • 1 Fernández J, Navasa M, Gómez J. , et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35 (01) 140-148
    CrossrefPubMedGoogle Scholar
  • 2 Bajaj JS, O'Leary JG, Reddy KR. , et al; NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012; 56 (06) 2328-2335
    CrossrefPubMedGoogle Scholar
  • 3 Bajaj JS, O'Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut 2012; 61 (08) 1219-1225
    CrossrefPubMedGoogle Scholar
  • 4 Fernández J, Acevedo J, Castro M. , et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55 (05) 1551-1561
    CrossrefPubMedGoogle Scholar
  • 5 Arvaniti V, D'Amico G, Fede G. , et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139 (04) 1246-1256 , 1256.e1–1256.e5
    CrossrefPubMedGoogle Scholar
  • 6 Nahon P, Lescat M, Layese R. , et al; ANRS CO12 CirVir and Microcir Groups. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut 2017; 66 (02) 330-341
    CrossrefPubMedGoogle Scholar
  • 7 Bajaj JS, O'Leary JG, Reddy KR. , et al; North American Consortium For The Study Of End-Stage Liver Disease (NACSELD). Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014; 60 (01) 250-256
    CrossrefPubMedGoogle Scholar
  • 8 Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut 2017; 66 (03) 541-553
    CrossrefPubMedGoogle Scholar
  • 9 Moreau R, Jalan R, Gines P. , et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
    CrossrefPubMedGoogle Scholar
  • 10 Sarin SK, Kedarisetty CK, Abbas Z. , et al; APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int 2014; 8 (04) 453-471
    CrossrefPubMedGoogle Scholar
  • 11 Wu T, Li J, Shao L. , et al; Chinese Group on the Study of Severe Hepatitis B (COSSH). Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut 2017; ;gutjnl-2017-314641 DOI: 10.1136/gutjnl-2017-314641.
    CrossrefPubMedGoogle Scholar
  • 12 Shi Y, Yang Y, Hu Y. , et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 2015; 62 (01) 232-242
    CrossrefPubMedGoogle Scholar
  • 13 Mücke MM, Rumyantseva T, Mücke VT. , et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality. Liver Int 2018; 38 (04) 645-653
    CrossrefPubMedGoogle Scholar
  • 14 Fernández J, Acevedo J, Wiest R. , et al; European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 2017; ;gutjnl-2017-314240 DOI: 10.1136/gutjnl-2017-314240.
    CrossrefPubMedGoogle Scholar
  • 15 Li H, Chen LY, Zhang NN. , et al. Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Sci Rep 2016; 6: 25487
    CrossrefPubMedGoogle Scholar
  • 16 Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18 (03) 353-358
    CrossrefPubMedGoogle Scholar
  • 17 Yoshida H, Hamada T, Inuzuka S, Ueno T, Sata M, Tanikawa K. Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroenterol 1993; 88 (12) 2067-2071
    PubMedGoogle Scholar
  • 18 Deschênes M, Villeneuve JP. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol 1999; 94 (08) 2193-2197
    CrossrefPubMedGoogle Scholar
  • 19 Thulstrup AM, Sørensen HT, Schønheyder HC, Møller JK, Tage-Jensen U. Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis 2000; 31 (06) 1357-1361
    CrossrefPubMedGoogle Scholar
  • 20 Merli M, Lucidi C, Di Gregorio V. , et al. An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: a randomized trial. Hepatology 2016; 63 (05) 1632-1639
    CrossrefPubMedGoogle Scholar
  • 21 Fernández J, Bert F, Nicolas-Chanoine MH. The challenges of multi-drug-resistance in hepatology. J Hepatol 2016; 65 (05) 1043-1054
    CrossrefPubMedGoogle Scholar
  • 22 Gustot T, Felleiter P, Pickkers P. , et al; EPIC II Group of Investigators. Impact of infection on the prognosis of critically ill cirrhotic patients: results from a large worldwide study. Liver Int 2014; 34 (10) 1496-1503
    CrossrefPubMedGoogle Scholar
  • 23 Karvellas CJ, Pink F, McPhail M. , et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med 2010; 38 (01) 121-126
    CrossrefPubMedGoogle Scholar
  • 24 Sarin SK, Kumar A, Almeida JA. , et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009; 3 (01) 269-282
    CrossrefPubMedGoogle Scholar
  • 25 Wasmuth HE, Kunz D, Yagmur E. , et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol 2005; 42 (02) 195-201
    CrossrefPubMedGoogle Scholar
  • 26 Jalan R, Fernandez J, Wiest R. , et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60 (06) 1310-1324
    CrossrefPubMedGoogle Scholar
  • 27 Tandon P, Abraldes JG, Keough A. , et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics. Clin Gastroenterol Hepatol 2015; 13 (06) 1189-96.e2
    CrossrefPubMedGoogle Scholar
  • 28 Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 2014; 61 (06) 1385-1396
    CrossrefPubMedGoogle Scholar
  • 29 Ramos JM, Vidal I, Bellot P, Gómez-Hurtado I, Zapater P, Such J. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis. Gut 2016; 65 (01) 182-183
    CrossrefPubMedGoogle Scholar
  • 30 Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016; 64 (04) 1265-1272
    CrossrefPubMedGoogle Scholar
  • 31 Fernández J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology 2016; 63 (06) 2019-2031
    CrossrefPubMedGoogle Scholar
  • 32 Gustot T, Fernandez J, Szabo G. , et al. Sepsis in alcohol-related liver disease. J Hepatol 2017; 67 (05) 1031-1050
    CrossrefPubMedGoogle Scholar
  • 33 Louvet A, Wartel F, Castel H. , et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137 (02) 541-548
    CrossrefPubMedGoogle Scholar
  • 34 Sargenti K, Prytz H, Nilsson E, Bertilsson S, Kalaitzakis E. Bacterial infections in alcoholic and nonalcoholic liver cirrhosis. Eur J Gastroenterol Hepatol 2015; 27 (09) 1080-1086
    CrossrefPubMedGoogle Scholar
  • 35 Vergis N, Atkinson SR, Knapp S. , et al. In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA. Gastroenterology 2017; 152 (05) 1068-1077.e4
    CrossrefPubMedGoogle Scholar
  • 36 Thévenot T, Bureau C, Oberti F. , et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2015; 62 (04) 822-830
    CrossrefPubMedGoogle Scholar
  • 37 Wong F, O'Leary JG, Reddy KR. , et al; North American Consortium for Study of End-Stage Liver Disease. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013; 145 (06) 1280-8.e1
    CrossrefPubMedGoogle Scholar
  • 38 Plessier A, Denninger MH, Consigny Y. , et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 2003; 23 (06) 440-448
    CrossrefPubMedGoogle Scholar
  • 39 Merli M, Lucidi C, Pentassuglio I. , et al. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. J Hepatol 2013; 59 (02) 243-250
    CrossrefPubMedGoogle Scholar
  • 40 Singer M, Deutschman CS, Seymour CW. , et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (08) 801-810
    CrossrefPubMedGoogle Scholar
  • 41 Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009; 50 (06) 2022-2033
    CrossrefPubMedGoogle Scholar
  • 42 Clària J, Stauber RE, Coenraad MJ. , et al; CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF). Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016; 64 (04) 1249-1264
    CrossrefPubMedGoogle Scholar
  • 43 Grp SCCT; SepNet Critical Care Trials Group. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentrle INSEP study. Intensive Care Med 2016; 42 (12) 1980-1989
    CrossrefPubMedGoogle Scholar
  • 44 Twilla JD, Nair SP, Talwar M, Kovalic A, Satapathy SK. Severity of systemic inflammatory response syndrome affects outcomes in decompensated cirrhotics with spontaneous bacterial peritonitis. Am J Gastroenterol 2016; 111 (07) 1043-1045
    CrossrefPubMedGoogle Scholar
  • 45 Angeli P, Tonon M, Pilutti C, Morando F, Piano S. Sepsis-induced acute kidney injury in patients with cirrhosis. Hepatol Int 2016; 10 (01) 115-123
    CrossrefPubMedGoogle Scholar
  • 46 Galbois A, Bigé N, Pichereau C. , et al. Exploration of skin perfusion in cirrhotic patients with septic shock. J Hepatol 2015; 62 (03) 549-555
    CrossrefPubMedGoogle Scholar
  • 47 Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care 2012; 16 (06) R227
    CrossrefPubMedGoogle Scholar
  • 48 Michelena J, Altamirano J, Abraldes JG. , et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology 2015; 62 (03) 762-772
    CrossrefPubMedGoogle Scholar
  • 49 Katoonizadeh A, Laleman W, Verslype C. , et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010; 59 (11) 1561-1569
    CrossrefPubMedGoogle Scholar
  • 50 Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut 2016; 65 (12) 2035-2044
    CrossrefPubMedGoogle Scholar
  • 51 Bajaj JS, Heuman DM, Hylemon PB. , et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (05) 940-947
    CrossrefPubMedGoogle Scholar
  • 52 Hackstein CP, Assmus LM, Welz M. , et al. Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis. Gut 2017; 66 (03) 507-518
    CrossrefPubMedGoogle Scholar
  • 53 Selvapatt N, Singanayagam A, Wendon J, Antoniades CG. Understanding infection susceptibility in patients with acute-on-chronic liver failure. Intensive Care Med 2014; 40 (09) 1363-1366
    CrossrefPubMedGoogle Scholar
  • 54 Bernsmeier C, Singanayagam A, Patel VC, Wendon J, Antoniades CG. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. Immunotherapy 2015; 7 (06) 641-654
    CrossrefPubMedGoogle Scholar
  • 55 Bernsmeier C, Triantafyllou E, Brenig R. , et al. CD14+CD15-HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut 2017; ;gutjnl-2017-314184 DOI: 10.1136/gutjnl-2017-314184.
    CrossrefPubMedGoogle Scholar
  • 56 Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010; 51 (04) 1327-1333
    CrossrefPubMedGoogle Scholar
  • 57 Senkerikova R, de Mare-Bredemeijer E, Frankova S. , et al. Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation. J Hepatol 2014; 60 (04) 773-781
    CrossrefPubMedGoogle Scholar
  • 58 Bernsmeier C, Pop OT, Singanayagam A. , et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology 2015; 148 (03) 603-615.e14
    CrossrefPubMedGoogle Scholar
  • 59 Choudhury A, Kumar M, Sharma BC. , et al; APASL ACLF working party. Systemic inflammatory response syndrome in acute-on-chronic liver failure: relevance of ‘golden window’: a prospective study. J Gastroenterol Hepatol 2017; 32 (12) 1989-1997
    CrossrefPubMedGoogle Scholar
  • 60 Merli M, Lucidi C, Giannelli V. , et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010; 8 (11) 979-985
    CrossrefPubMedGoogle Scholar
  • 61 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (03) 397-417
    CrossrefPubMedGoogle Scholar
  • 62 Mandell LA, Wunderink RG, Waterer GW. Community-acquired pneumonia. N Engl J Med 2015; 372 (03) 293-294
    PubMedGoogle Scholar
  • 63 Boaretti M, Castellani F, Merli M, Lucidi C, Lleo MM. Presence of multiple bacterial markers in clinical samples might be useful for presumptive diagnosis of infection in cirrhotic patients with culture-negative reports. Eur J Clin Microbiol Infect Dis 2016; 35 (03) 433-441
    CrossrefPubMedGoogle Scholar
  • 64 Papp M, Vitalis Z, Altorjay I. , et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. Liver Int 2012; 32 (04) 603-611
    CrossrefPubMedGoogle Scholar
  • 65 Lin KH, Wang FL, Wu MS. , et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis. Diagn Microbiol Infect Dis 2014; 80 (01) 72-78
    CrossrefPubMedGoogle Scholar
  • 66 Parsi MA, Saadeh SN, Zein NN. , et al. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology 2008; 135 (03) 803-807
    CrossrefPubMedGoogle Scholar
  • 67 Enomoto H, Inoue S, Matsuhisa A. , et al. Development of a new in situ hybridization method for the detection of global bacterial DNA to provide early evidence of a bacterial infection in spontaneous bacterial peritonitis. J Hepatol 2012; 56 (01) 85-94
    CrossrefPubMedGoogle Scholar
  • 68 Papp M, Sipeki N, Vitalis Z. , et al. High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis. J Hepatol 2013; 59 (03) 457-466
    CrossrefPubMedGoogle Scholar
  • 69 Tornai T, Vitalis Z, Sipeki N. , et al. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection. Liver Int 2016; 36 (11) 1628-1638
    CrossrefPubMedGoogle Scholar
  • 70 Wu Y, Wang M, Zhu Y, Lin S. Serum interleukin-6 in the diagnosis of bacterial infection in cirrhotic patients: A meta-analysis. Medicine (Baltimore) 2016; 95 (41) e5127
    CrossrefPubMedGoogle Scholar
  • 71 Xin J, Ding W, Hao S. , et al. Serum macrophage inflammatory protein 3α levels predict the severity of HBV-related acute-on-chronic liver failure. Gut 2016; 65 (02) 355-357
    CrossrefPubMedGoogle Scholar
  • 72 Kang DK, Ali MM, Zhang K. , et al. Rapid detection of single bacteria in unprocessed blood using Integrated Comprehensive Droplet Digital Detection. Nat Commun 2014; 5: 5427
    CrossrefPubMedGoogle Scholar
  • 73 Shen H, Wang J, Liu H. , et al. Rapid and selective detection of pathogenic bacteria in bloodstream infections with aptamer-based recognition. ACS Appl Mater Interfaces 2016; 8 (30) 19371-19378
    CrossrefPubMedGoogle Scholar
  • 74 Cao Z, Lu X, Li Z. , et al. The role of bacterial infection (BI) in decompensated cirrhosis patients with or without acute-on-chronic liver failure (ACLF). J Hepatol 2017; 66: S344-S344
    PubMedGoogle Scholar
  • 75 Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56 (Suppl. 01) S1-S12
    CrossrefPubMedGoogle Scholar
  • 76 Fernández J, Navasa M, Planas R. , et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133 (03) 818-824
    CrossrefPubMedGoogle Scholar
  • 77 Ginés P, Rimola A, Planas R. , et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (4 Pt 1): 716-724
    CrossrefPubMedGoogle Scholar
  • 78 Fernández J, Ruiz del Arbol L, Gómez C. , et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131 (04) 1049-1056 , quiz 1285
    CrossrefPubMedGoogle Scholar
  • 79 Terg R, Fassio E, Guevara M. , et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48 (05) 774-779
    CrossrefPubMedGoogle Scholar
  • 80 Lontos S, Gow PJ, Vaughan RB, Angus PW. Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2008; 23 (02) 252-255
    CrossrefPubMedGoogle Scholar
  • 81 Lontos S, Shelton E, Angus PW. , et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis 2014; 15 (05) 260-267
    CrossrefPubMedGoogle Scholar
  • 82 Yan K, Garcia-Tsao G. Novel prevention strategies for bacterial infections in cirrhosis. Expert Opin Pharmacother 2016; 17 (05) 689-701
    CrossrefPubMedGoogle Scholar
  • 83 Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol 2017; 67 (05) 1084-1103
    CrossrefPubMedGoogle Scholar
  • 84 Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006; 45 (05) 744-757
    CrossrefPubMedGoogle Scholar
  • 85 Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48 (06) 945-951
    CrossrefPubMedGoogle Scholar
  • 86 Bajaj JS, Heuman DM, Hylemon PB. , et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014; 39 (10) 1113-1125
    CrossrefPubMedGoogle Scholar
  • 87 Meiphani A, Ramesh M, Salgia R. Successful outcomes of fecal microbiota transplantation in patients with chronic liver disease. Hepatology 2016; 64 (Suppl. 01) 1016A-1017A
    PubMedGoogle Scholar
  • 88 Bajaj JS, Kassam Z, Fagan A. , et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017; 66 (06) 1727-1738
    CrossrefPubMedGoogle Scholar
  • 89 Merli M, Lucidi C, Di Gregorio V. , et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int 2015; 35 (02) 362-369
    CrossrefPubMedGoogle Scholar
  • 90 Úbeda M, Lario M, Muñoz L. , et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 2016; 64 (05) 1049-1057
    CrossrefPubMedGoogle Scholar
  • 91 Madsen BS, Havelund T, Krag A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv Ther 2013; 30 (07) 659-670
    CrossrefPubMedGoogle Scholar
  • 92 Mookerjee RP, Pavesi M, Thomsen KL. , et al; CANONIC Study Investigators of the EASL-CLIF Consortium. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol 2016; 64 (03) 574-582
    CrossrefPubMedGoogle Scholar
  • 93 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
    CrossrefPubMedGoogle Scholar
  • 94 Kalambokis GN, Baltayiannis G, Christou L, Christodoulou D. Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use. Gut 2016; 65 (07) 1228-1230
    CrossrefPubMedGoogle Scholar
  • 95 Madsen BS, Nielsen KF, Fialla AD, Krag A. Keep the sick from harm in spontaneous bacterial peritonitis: dose of beta blockers matters. J Hepatol 2016; 64 (06) 1455-1456
    CrossrefPubMedGoogle Scholar
  • 96 Horvath A, Leber B, Schmerboeck B. , et al. Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Aliment Pharmacol Ther 2016; 44 (09) 926-935
    CrossrefPubMedGoogle Scholar
  • 97 Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013; 58 (05) 1836-1846
    CrossrefPubMedGoogle Scholar
  • 98 Gustot T. Beneficial role of G-CSF in acute-on-chronic liver failure: effects on liver regeneration, inflammation/immunoparalysis or both?. Liver Int 2014; 34 (04) 484-486
    CrossrefPubMedGoogle Scholar
  • 99 Khanam A, Trehanpati N, Garg V. , et al. Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure. Liver Int 2014; 34 (04) 505-513
    CrossrefPubMedGoogle Scholar
  • 100 Kedarisetty CK, Anand L, Bhardwaj A. , et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 2015; 148 (07) 1362-70.e7
    CrossrefPubMedGoogle Scholar
  • 101 Anty R, Tonohouan M, Ferrari-Panaia P. , et al. Low levels of 25-hydroxy vitamin D are independently associated with the risk of bacterial infection in cirrhotic patients. Clin Transl Gastroenterol 2014; 5: e56
    CrossrefPubMedGoogle Scholar
  • 102 Anty R, Anstee QM, Gual P, Tran A. Prophylaxis of bacterial infections in cirrhosis: is an optimal 25-OH vitamin D level required?. J Hepatol 2014; 61 (04) 965-966
    CrossrefPubMedGoogle Scholar
  • 103 Ariza X, Castellote J, Lora-Tamayo J. , et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56 (04) 825-832
    CrossrefPubMedGoogle Scholar
  • 104 Ison MG. Empiric treatment of nosocomial spontaneous bacterial peritonitis: one size does not fit all. Hepatology 2016; 63 (04) 1083-1085
    CrossrefPubMedGoogle Scholar
  • 105 Bartoletti M, Giannella M, Caraceni P. , et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J Hepatol 2014; 61 (01) 51-58
    CrossrefPubMedGoogle Scholar
  • 106 Sargenti K, Prytz H, Strand A, Nilsson E, Kalaitzakis E. Healthcare-associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcome. Liver Int 2015; 35 (02) 391-400
    CrossrefPubMedGoogle Scholar
  • 107 Piano S, Fasolato S, Salinas F. , et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology 2016; 63 (04) 1299-1309
    CrossrefPubMedGoogle Scholar
  • 108 Jalan R, Yurdaydin C, Bajaj JS. , et al; World Gastroenterology Organization Working Party. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology 2014; 147 (01) 4-10
    CrossrefPubMedGoogle Scholar